Autores: Cabrera Álvarez Guillermo, Gómez Galicia Diana, Rodríguez Fragoso Lourdes, Madrid Marina Vicente, Cañedo Dorantes Luis, Sánchez Alemán Miguel Ángel, Méndez Sánchez Nahum, Reyes Esparza Jorge Alberto
Background: Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV. Objective: The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF and ribavirin treatment in patients with HCV. Material and methods: We included patients whose platelets were < 90,000/mm3 and who were undergoing antiviral treatment. Danazol (300-600 mg/day) was administered during and until the end of antiviral therapy [7.6 months (2 to 11 months)]. The monitoring was performed through platelet analysis and liver function tests. A viral load test was done at the beginning and end of treatment. Fortynine patients receiving a combined therapy of PEG-INF, ribavirin and Danazol increased their platelet levels to 121,081/mm3 (46,000-216,000/mm3); 10.6% of patients gained > 100,000 platelets/mm3, and 71% of patients maintained their initial platelet levels. Sustained viral response (SVR) was achieved in 63% of patients. SVR rates were high in patients with genotype non 1 (78.7%) and decreased in patients with genotype 1 (60.1%). The increase in platelet levels was associated to an increase in fibrinogen levels and a decrease in the activity of ALT. By contrast, patients without SVR presented a delayed response to increased platelet levels and showed no significant improvement in liver function when they received Danazol. Conclusion: Danazol can be used along with PEG-INF and ribavirin to treat thrombocytopenia in patients with HCV.
2011-09-13 | 593 visitas | Evalua este artículo 0 valoraciones
Vol. 10 Núm.4. Octubre-Diciembre 2011 Pags. 458-468 Ann Hepatol 2011; 10(4)